by TractManager | Dec 11, 2023 | Emerging Technology Report
Lovotibeglogene autotemcel (Lyfgenia; Bluebird Bio Inc.) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.
by TractManager | Dec 5, 2023 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Vivistim Paired Vagus Nerve Stimulation (VNS) System (MicroTransponder Inc.) for rehabilitation of upper...
by TractManager | Dec 4, 2023 | Emerging Technology Report
Aortix is an investigational percutaneous mechanical circulatory support device in development for the treatment of chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure with worsening renal...
by TractManager | Dec 1, 2023 | Emerging Technology Report
Sonpiretigene isteparvovec is an investigational gene therapy for retinitis pigmentosa, administered as an intravitreal injection.
Recent Comments